Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Small Cell Lung Carcinoma 3Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Peritoneal Neoplasms 1Osteosarcoma 1Liver, Cancer of, Primary Resectable 1Hepatocellular Carcinoma Resectable 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1Acute Toxic Effects 1

Interventions

Methotrexate 21Ifosfamide 21Cyclophosphamide 19Doxorubicin 17Cisplatin 14Filgrastim 13Gemcitabine 12Etoposide 11Leucovorin 9apatinib 8fludarabine 7glucarpidase 6Vincristine 6Temozolomide 6Radiotherapy 6Nivolumab 6Neoadjuvant Therapy 6Drug Therapy 6Carboplatin 6regorafenib 5cabozantinib 5Zoledronic Acid 5Topotecan 5Mesna 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Docetaxel 5pembrolizumab 4pegfilgrastim 4camrelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Osteosarcoma × lobaplatin × Clear all
NCT06714383 2024-12-03

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Peking University People's Hospital

Phase 2 Recruiting
50 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡